Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (261-270 of 504) with videos related to

Pageof 51
Sort By:
Blood|April 20, 2002
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemiaMichele Milella, Zeev Estrov, Steven M Kornblau, et al.
Blood|February 11, 2012
The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivativesSteven H Bernstein, Sundararajan Venkatesh, Min Li, et al.
Cancer Research|November 3, 2004
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemiaMarina Konopleva, Twee Tsao, Zeev Estrov, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortalityKai Sun, Minghui Li, Marina Konopleva, et al.
Molecular Cancer Therapeutics|March 1, 2006
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cellsMarina Konopleva, Weiguo Zhang, Yue-Xi Shi, et al.
Nuklearmedizin. Nuclear Medicine|July 16, 2016
[Therapy of bone metastases with radium-223. German guidelines]Thorsten D Pöppel, Michael Andreeff, Alexander Becherer, et al.
Cancer Medicine|July 20, 2024
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignanciesCourtney D DiNardo, Rebecca Olin, Eunice S Wang, et al.
Pediatric Blood & Cancer|June 2, 2005
Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrowMehmet Fatih Okcu, Rui-Yu Wang, Carlos Bueso-Ramos, et al.
Oncotarget|March 10, 2016
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling networkBing Z Carter, Po Yee Mak, Ye Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Pageof 51

Showing results (261-270 of 504) with videos related to

Sort By:
Pageof 51
Blood|April 20, 2002
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemiaMichele Milella, Zeev Estrov, Steven M Kornblau, et al.
Blood|February 11, 2012
The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivativesSteven H Bernstein, Sundararajan Venkatesh, Min Li, et al.
Cancer Research|November 3, 2004
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemiaMarina Konopleva, Twee Tsao, Zeev Estrov, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortalityKai Sun, Minghui Li, Marina Konopleva, et al.
Molecular Cancer Therapeutics|March 1, 2006
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cellsMarina Konopleva, Weiguo Zhang, Yue-Xi Shi, et al.
Nuklearmedizin. Nuclear Medicine|July 16, 2016
[Therapy of bone metastases with radium-223. German guidelines]Thorsten D Pöppel, Michael Andreeff, Alexander Becherer, et al.
Cancer Medicine|July 20, 2024
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignanciesCourtney D DiNardo, Rebecca Olin, Eunice S Wang, et al.
Pediatric Blood & Cancer|June 2, 2005
Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrowMehmet Fatih Okcu, Rui-Yu Wang, Carlos Bueso-Ramos, et al.
Oncotarget|March 10, 2016
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling networkBing Z Carter, Po Yee Mak, Ye Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Pageof 51